IL7 and neoplasm: The anti-tumor efficacies of IL-12/IL-7 and IL-12/IFN-α cytokine mRNA doublets and equiquantity triplet (1:1:1 of IL-12/IL-7/IFN-α) were not significantly different from that of the IL-12 mRNA monotherapy, as evidenced by their comparable TGI indexes and median survival times.